JP2010520308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520308A5 JP2010520308A5 JP2009552887A JP2009552887A JP2010520308A5 JP 2010520308 A5 JP2010520308 A5 JP 2010520308A5 JP 2009552887 A JP2009552887 A JP 2009552887A JP 2009552887 A JP2009552887 A JP 2009552887A JP 2010520308 A5 JP2010520308 A5 JP 2010520308A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical formulation
- alkyl
- compound according
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 102100036832 Steroid hormone receptor ERR1 Human genes 0.000 claims 6
- 101710205336 Steroid hormone receptor ERR1 Proteins 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000006467 substitution reaction Methods 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 230000003287 optical effect Effects 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 3
- 210000000845 cartilage Anatomy 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000000883 anti-obesity agent Substances 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229940125425 inverse agonist Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000025940 Back injury Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 229940124802 CB1 antagonist Drugs 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 102000030595 Glucokinase Human genes 0.000 claims 1
- 108010021582 Glucokinase Proteins 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000022159 cartilage development Effects 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000019439 energy homeostasis Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000407 monoamine reuptake Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 1
- 229960001243 orlistat Drugs 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000000010 osteolytic effect Effects 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 claims 1
- 229960003015 rimonabant Drugs 0.000 claims 1
- 201000001223 septic arthritis Diseases 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- FZKBWHATZXQBRD-UKWGHVSLSA-N CCOc(cc(/C=C1\SC(N(C2)CC2C(O)=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N Chemical compound CCOc(cc(/C=C1\SC(N(C2)CC2C(O)=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N FZKBWHATZXQBRD-UKWGHVSLSA-N 0.000 description 4
- UCVUGJVHSDPNRH-NHDPSOOVSA-N COc(cc(/C=C1\SC(N(CCC2)CC2O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N Chemical compound COc(cc(/C=C1\SC(N(CCC2)CC2O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N UCVUGJVHSDPNRH-NHDPSOOVSA-N 0.000 description 4
- JBYBRFVTFRLTQA-GRSHGNNSSA-N COc(cc(/C=C1\SC(N(CCN2)CC2=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N Chemical compound COc(cc(/C=C1\SC(N(CCN2)CC2=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N JBYBRFVTFRLTQA-GRSHGNNSSA-N 0.000 description 4
- SXDYOERGUNCIBI-JMIUGGIZSA-N Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(C)CC(CO)O)=NC1=O)c1)c1OC Chemical compound Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(C)CC(CO)O)=NC1=O)c1)c1OC SXDYOERGUNCIBI-JMIUGGIZSA-N 0.000 description 4
- OYELVRXAMPHDCQ-NVMNQCDNSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(CCN2)CC2=O)=NC1=O)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(CCN2)CC2=O)=NC1=O)c1)c1F OYELVRXAMPHDCQ-NVMNQCDNSA-N 0.000 description 4
- NRKSJHIPWOQYPY-UWVJOHFNSA-N COc(cc(/C=C1\SC(N(C2)CC2C(O)=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N Chemical compound COc(cc(/C=C1\SC(N(C2)CC2C(O)=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N NRKSJHIPWOQYPY-UWVJOHFNSA-N 0.000 description 3
- CWDHNITZQNNCGN-ODLFYWEKSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(CCO)CCO)=NC1=O)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(CCO)CCO)=NC1=O)c1)c1F CWDHNITZQNNCGN-ODLFYWEKSA-N 0.000 description 3
- DJUUVACFPGYCCL-BKUYFWCQSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCCCN(CCC2)C2=O)=NC1=O)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCCCN(CCC2)C2=O)=NC1=O)c1)c1F DJUUVACFPGYCCL-BKUYFWCQSA-N 0.000 description 3
- XEDDRNQLJVHPLS-OCKHKDLRSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCC[n]2ncnc2)=NC1=O)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCC[n]2ncnc2)=NC1=O)c1)c1F XEDDRNQLJVHPLS-OCKHKDLRSA-N 0.000 description 3
- 0 *c(c(*)c1*)ccc1Oc1ccc(C=C(*C(N(*)*)=N2)C2=O)cc1* Chemical compound *c(c(*)c1*)ccc1Oc1ccc(C=C(*C(N(*)*)=N2)C2=O)cc1* 0.000 description 2
- VJQOPAPPXUFNGR-UWVJOHFNSA-N CN(CC(CO)O)C(S/C1=C\c(cc2)cc(F)c2Oc(c(C(F)(F)F)c2)ccc2C#N)=NC1=O Chemical compound CN(CC(CO)O)C(S/C1=C\c(cc2)cc(F)c2Oc(c(C(F)(F)F)c2)ccc2C#N)=NC1=O VJQOPAPPXUFNGR-UWVJOHFNSA-N 0.000 description 2
- GVFDJARVUPVMGP-UWVJOHFNSA-N COC(c(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(C2)CC2C(O)=O)=NC1=O)c1)c1OC)=O Chemical compound COC(c(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(C2)CC2C(O)=O)=NC1=O)c1)c1OC)=O GVFDJARVUPVMGP-UWVJOHFNSA-N 0.000 description 2
- UWYUHJIECTYDDL-JMIUGGIZSA-N COc(cc(/C=C1\SC(N(CCC2)CC2O)=NC1=O)cc1)c1Oc1ccc(C(F)(F)F)cc1C(F)(F)F Chemical compound COc(cc(/C=C1\SC(N(CCC2)CC2O)=NC1=O)cc1)c1Oc1ccc(C(F)(F)F)cc1C(F)(F)F UWYUHJIECTYDDL-JMIUGGIZSA-N 0.000 description 2
- IYEVNMJHAJGETF-HMAPJEAMSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCCCN2CCOCC2)=NC1=O)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCCCN2CCOCC2)=NC1=O)c1)c1F IYEVNMJHAJGETF-HMAPJEAMSA-N 0.000 description 2
- IKRHZHZMTKGZLV-MFOYZWKCSA-N CC(C1C(F)(F)F)C(C#N)=CC=C1Oc(ccc(/C=C1\SC(NCCF)=NC1=O)c1)c1F Chemical compound CC(C1C(F)(F)F)C(C#N)=CC=C1Oc(ccc(/C=C1\SC(NCCF)=NC1=O)c1)c1F IKRHZHZMTKGZLV-MFOYZWKCSA-N 0.000 description 1
- VAMNAJHOETUHOK-IUXPMGMMSA-N CC1(C=C(C(F)(F)F)C(Oc(ccc(/C=C2\SC(NCc3nnn[nH]3)=NC2=O)c2)c2OC)=CC1)C#N Chemical compound CC1(C=C(C(F)(F)F)C(Oc(ccc(/C=C2\SC(NCc3nnn[nH]3)=NC2=O)c2)c2OC)=CC1)C#N VAMNAJHOETUHOK-IUXPMGMMSA-N 0.000 description 1
- OWTCDDOUMQBIKF-JMIUGGIZSA-N CCC(CNC(S/C1=C\c(cc2)cc(OC)c2OC(C(C(F)(F)F)=C2)=CCC2C#N)=NC1=O)C(O)=O Chemical compound CCC(CNC(S/C1=C\c(cc2)cc(OC)c2OC(C(C(F)(F)F)=C2)=CCC2C#N)=NC1=O)C(O)=O OWTCDDOUMQBIKF-JMIUGGIZSA-N 0.000 description 1
- BZEHWTKDULESGA-UKWGHVSLSA-N CN(CC(CO)O)C(S/C1=C\c(cc2)cc(OC)c2Oc(c(C(F)(F)F)c2)ccc2C#N)=NC1=O Chemical compound CN(CC(CO)O)C(S/C1=C\c(cc2)cc(OC)c2Oc(c(C(F)(F)F)c2)ccc2C#N)=NC1=O BZEHWTKDULESGA-UKWGHVSLSA-N 0.000 description 1
- UJNFXVHMVVWJQI-UKWGHVSLSA-N CN(CC(CO)O)C(S1)=NC2OC2/C1=C/c(cc1)cc(OC)c1Oc(c(C(F)(F)F)c1)ccc1C#N Chemical compound CN(CC(CO)O)C(S1)=NC2OC2/C1=C/c(cc1)cc(OC)c1Oc(c(C(F)(F)F)c1)ccc1C#N UJNFXVHMVVWJQI-UKWGHVSLSA-N 0.000 description 1
- KMCGQWLVQNXFIM-JAIQZWGSSA-N CN(CCN(C1)C(S/C2=C\c(cc3)cc(OC)c3Oc(c(C(F)(F)F)c3)ccc3C#N)=NC2=O)C1=O Chemical compound CN(CCN(C1)C(S/C2=C\c(cc3)cc(OC)c3Oc(c(C(F)(F)F)c3)ccc3C#N)=NC2=O)C1=O KMCGQWLVQNXFIM-JAIQZWGSSA-N 0.000 description 1
- HTIOZYSUZOLCDN-NVMNQCDNSA-N COc(cc(/C=C1\SC(N(CCN2)CC2=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1Cl Chemical compound COc(cc(/C=C1\SC(N(CCN2)CC2=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1Cl HTIOZYSUZOLCDN-NVMNQCDNSA-N 0.000 description 1
- NKMFSXOIHSQSSD-ZDLGFXPLSA-N COc(cc(/C=C1\SC(NCCNC(N)=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N Chemical compound COc(cc(/C=C1\SC(NCCNC(N)=O)=NC1=O)cc1)c1Oc(c(C(F)(F)F)c1)ccc1C#N NKMFSXOIHSQSSD-ZDLGFXPLSA-N 0.000 description 1
- MFKHDKVERILUGO-ODLFYWEKSA-N Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(CCN2)CC2=O)=NC1=O)c1)c1OC Chemical compound Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(CCN2)CC2=O)=NC1=O)c1)c1OC MFKHDKVERILUGO-ODLFYWEKSA-N 0.000 description 1
- XZPJMFQTIPSYFE-APSNUPSMSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C(/C1)\SC(NCC[n]2ncnc2)=NC1=O)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C(/C1)\SC(NCC[n]2ncnc2)=NC1=O)c1)c1F XZPJMFQTIPSYFE-APSNUPSMSA-N 0.000 description 1
- VOZPEPWRXVBLSJ-WSVATBPTSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(C2)CC2C(O)=O)=NC1=O)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(C2)CC2C(O)=O)=NC1=O)c1)c1F VOZPEPWRXVBLSJ-WSVATBPTSA-N 0.000 description 1
- FFJBZXIFGKSWEG-MFOYZWKCSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(CCO)CCO)=NCOC1)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(N(CCO)CCO)=NCOC1)c1)c1F FFJBZXIFGKSWEG-MFOYZWKCSA-N 0.000 description 1
- LTZSVOQWUKDFPX-BKUYFWCQSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCCCN(CCC2)C2O)=NC1=O)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCCCN(CCC2)C2O)=NC1=O)c1)c1F LTZSVOQWUKDFPX-BKUYFWCQSA-N 0.000 description 1
- SLDPLSAOCDZFCB-MFOYZWKCSA-N N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCCF)=NC1=O)c1)c1F Chemical compound N#Cc(cc1C(F)(F)F)ccc1Oc(ccc(/C=C1\SC(NCCF)=NC1=O)c1)c1F SLDPLSAOCDZFCB-MFOYZWKCSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89346407P | 2007-03-07 | 2007-03-07 | |
| PCT/US2008/056029 WO2008109737A1 (en) | 2007-03-07 | 2008-03-06 | Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520308A JP2010520308A (ja) | 2010-06-10 |
| JP2010520308A5 true JP2010520308A5 (enExample) | 2011-03-24 |
Family
ID=39530136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552887A Pending JP2010520308A (ja) | 2007-03-07 | 2008-03-06 | エストロゲン関連受容体−アルファモジュレーターとしての置換フェノキシアミノチアゾロン |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8580832B2 (enExample) |
| EP (1) | EP2134698A1 (enExample) |
| JP (1) | JP2010520308A (enExample) |
| KR (1) | KR20090128454A (enExample) |
| CN (1) | CN101679327A (enExample) |
| AR (1) | AR065657A1 (enExample) |
| AU (1) | AU2008222755B2 (enExample) |
| BR (1) | BRPI0808776A2 (enExample) |
| CA (1) | CA2680212A1 (enExample) |
| CL (1) | CL2008000667A1 (enExample) |
| EA (1) | EA016887B1 (enExample) |
| IL (1) | IL200759A0 (enExample) |
| MX (1) | MX2009009520A (enExample) |
| NZ (1) | NZ579417A (enExample) |
| TW (1) | TW200902506A (enExample) |
| UA (1) | UA98484C2 (enExample) |
| WO (1) | WO2008109737A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| MY152078A (en) | 2007-09-14 | 2014-08-15 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
| CA2698929C (en) | 2007-09-14 | 2016-01-19 | Addex Pharma S.A. | 1,3-disubstituted-4-phenyl-1h-pyridin-2-ones |
| MX2010002538A (es) | 2007-09-14 | 2010-08-10 | Ortho Mcneil Janssen Pharm | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas. |
| ES2637794T3 (es) | 2007-11-14 | 2017-10-17 | Janssen Pharmaceuticals, Inc. | Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2 |
| AU2009289784B2 (en) | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| RU2517181C2 (ru) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов |
| CA2744138C (en) | 2008-11-28 | 2015-08-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| AU2010246609B2 (en) | 2009-05-12 | 2013-09-05 | Addex Pharma S.A. | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| EA020671B1 (ru) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 |
| JPWO2011016501A1 (ja) * | 2009-08-04 | 2013-01-10 | 武田薬品工業株式会社 | 癌の予防ないし治療薬 |
| WO2011019556A1 (en) | 2009-08-11 | 2011-02-17 | Janssen Pharmaceutica Nv | CO-CRYSTALLIZATION OF ERR-A α WITH A LIGAND THAT FORMS A REVERSIBLE CONVALENT BOND |
| US8927297B2 (en) * | 2009-08-11 | 2015-01-06 | Janssen Pharmaceutica N.V. | Methods to measure dissociation rates for ligands that form reversible covalent bonds |
| JP2013514385A (ja) | 2009-12-18 | 2013-04-25 | ヤンセン ファーマシューティカ エヌ．ベー． | エストロゲン関連受容体αモジュレーターとしての置換アミノチアゾロンインダゾール |
| EP2536716B1 (en) * | 2010-02-17 | 2014-05-21 | Janssen Pharmaceutica, N.V. | Aminothiazolones as estrogen related receptor-alpha modulators |
| US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| WO2012062751A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| CN103298809B (zh) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
| TW201311679A (zh) | 2011-08-04 | 2013-03-16 | Takeda Pharmaceutical | 含氮雜環化合物 |
| CA2868311C (en) | 2012-03-26 | 2021-06-22 | Nippon Chemiphar Co., Ltd. | Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| EP3050573B1 (en) | 2013-09-25 | 2019-12-11 | Nippon Chemiphar Co., Ltd. | Zaltoprofen for preventing metastasis of giant cell tumor that occurs in bone or soft parts, metastasis of chondrosarcoma, or metastasis of osteosarcoma |
| HUE045610T2 (hu) | 2014-01-21 | 2020-01-28 | Janssen Pharmaceutica Nv | 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait vagy ortosztérikus agonistáit tartalmazó kombinációk és alkalmazásuk |
| WO2015110435A1 (en) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20220004986A (ko) | 2019-03-28 | 2022-01-12 | 에시언트 파마슈티컬스 인코포레이티드 | Mas-관련 G-단백질 수용체 X4의 조절제 및 관련 제품 및 방법 |
| CN114341135B (zh) * | 2019-07-04 | 2025-03-18 | 领先制药控股公司 | 雌激素相关受体α(ERRα)调节剂 |
| CN112538038B (zh) * | 2019-09-20 | 2022-05-20 | 暨南大学 | 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用 |
| KR20220066822A (ko) | 2020-11-16 | 2022-05-24 | 경북대학교 산학협력단 | 골 질환 예방 또는 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5037842A (en) | 1990-06-05 | 1991-08-06 | Pfizer Inc. | Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents |
| JP2001072592A (ja) | 1999-07-01 | 2001-03-21 | Kyowa Hakko Kogyo Co Ltd | テロメラーゼ阻害剤 |
| AU5702201A (en) | 2000-04-13 | 2001-10-30 | Mayo Foundation | Abeta<sub>42</sub> lowering agents |
| DE10131899A1 (de) | 2001-07-04 | 2003-02-27 | Boehringer Ingelheim Pharma | In vitro-Screening-Assay für gamma-Secretase |
| EP1398029A1 (en) | 2002-09-10 | 2004-03-17 | LION Bioscience AG | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives |
| WO2006004555A1 (en) | 2004-06-30 | 2006-01-12 | Paysetter Pte Ltd | System and method for facilitating transfer of physical money and/or credit |
| EP1781271A1 (en) * | 2004-07-14 | 2007-05-09 | Janssen Pharmaceutica N.V. | Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases |
| US7977489B2 (en) * | 2004-10-22 | 2011-07-12 | Exelixis, Inc. | Benzylthiazolone inhibitors of estrogen-related receptors (ERR) |
-
2008
- 2008-03-06 CL CL2008000667A patent/CL2008000667A1/es unknown
- 2008-03-06 JP JP2009552887A patent/JP2010520308A/ja active Pending
- 2008-03-06 WO PCT/US2008/056029 patent/WO2008109737A1/en not_active Ceased
- 2008-03-06 US US12/043,311 patent/US8580832B2/en not_active Expired - Fee Related
- 2008-03-06 EA EA200970839A patent/EA016887B1/ru not_active IP Right Cessation
- 2008-03-06 TW TW097107931A patent/TW200902506A/zh unknown
- 2008-03-06 MX MX2009009520A patent/MX2009009520A/es unknown
- 2008-03-06 CA CA002680212A patent/CA2680212A1/en not_active Abandoned
- 2008-03-06 UA UAA200910122A patent/UA98484C2/ru unknown
- 2008-03-06 CN CN200880015410A patent/CN101679327A/zh active Pending
- 2008-03-06 NZ NZ579417A patent/NZ579417A/en not_active IP Right Cessation
- 2008-03-06 BR BRPI0808776-8A patent/BRPI0808776A2/pt not_active IP Right Cessation
- 2008-03-06 KR KR1020097020836A patent/KR20090128454A/ko not_active Withdrawn
- 2008-03-06 EP EP08731528A patent/EP2134698A1/en not_active Ceased
- 2008-03-06 AU AU2008222755A patent/AU2008222755B2/en not_active Expired - Fee Related
- 2008-03-07 AR ARP080100964A patent/AR065657A1/es not_active Application Discontinuation
-
2009
- 2009-09-06 IL IL200759A patent/IL200759A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520308A5 (enExample) | ||
| JP2010520306A5 (enExample) | ||
| JP2010520307A5 (enExample) | ||
| HRP20120160T1 (hr) | Supstituirani fenoksi n-alkilirani tiazoldindion kao modulatori estrogen srodnih alfa-receptora | |
| RU2470011C2 (ru) | Циклоалкиламины, содержащие в качестве заместителя фенил, как ингибиторы обратного захвата моноаминов | |
| JP2004514663A5 (enExample) | ||
| JP2020500862A5 (enExample) | ||
| AR065657A1 (es) | DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS. | |
| JP2009536629A5 (enExample) | ||
| JP2008521827A5 (enExample) | ||
| JP2012504133A5 (enExample) | ||
| JP2014513046A5 (enExample) | ||
| JP2015523339A5 (enExample) | ||
| JP6770511B2 (ja) | 心肺障害の処置のためのスフィンゴシン−１−リン酸受容体モジュレーター | |
| JP2009527462A5 (enExample) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| JP2014505017A5 (enExample) | ||
| JP2010526827A5 (enExample) | ||
| JP2010522710A5 (enExample) | ||
| JP2005505538A5 (enExample) | ||
| RU2013128973A (ru) | Соединения, активные в отношении кальций-чувствительных рецепторов | |
| RU2014119711A (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
| JPWO2023195529A5 (enExample) | ||
| JP2014504648A5 (enExample) | ||
| RU2012139459A (ru) | Аминотиазолоны для использования в качестве модуляторов родственных эстрогену рецепторов альфа |